Almost two years after announcing it would close a Lipitor-producing plant in Cork County, Ireland, Pfizer has officially said it will keep the plant operational. It turns out there is enough demand around the world for its off-patent cholesterol drug for the plant to remain open "for the foreseeable future."
It's official: Demand for the off-patent drug Lipitor has inspired Pfizer to keep an Irish plant it had slated for closure.
SINGAPORE--An Australia Federal Court justice dismissed a case brought by the nation's consumer watchdog agency, saying it failed to prove Pfizer Australia violated the law by muscling out the competition for its Lipitor (atorvastatin) anti-cholesterol drug.
A Pfizer plant in Ireland that was slated to close last year is still running strong, as sales of blockbuster cholesterol drug Lipitor remain vibrant in some parts of the world three years after losing its U.S. patent.
Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting blockbuster Lipitor.
Sales of Lipitor, the best-selling drug of all time, may be waning, but litigation over the cholesterol fighter is growing--a lot.
One hundred Irish Pfizer jobs once tapped for chopping are now safe, and the company's off-patent meds, like Lipitor, are the saviors.
It's a tale of two statin drugs and their attempts to keep market share--or build it, as the case may be. Pfizer rolled out a new version of its Lipitor copay discount program, and this time, it applies to patients covered via certain U.S. government programs.
Pfizer hasn't given up on pumping Lipitor for sales. Its latest marketing tactic? A replay of its bid to keep scripts coming after the statin drug lost patent protection in 2011. The company is rolling out another copay discount program, Lipitor Choice.
Time is running out before generics descend on Nexium, the stomach drug that rakes in nearly $4 billion a year for AstraZeneca. And in an effort to conserve sales, the British drugmaker is going where it's gone once before: a direct-to-patient delivery program it hopes will keep customers in its grasp.